BioRestorative Therapies’ Stockholders Approve Institutional Investor Agreement and Exchange Agreements

    NEXT STORY
    Generex Announces Webcast
    PREV STORY
    PAVmed Reports Second Quarter 2019 Financial Results and Provides Business Update
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Phase 2 data of aprocitentan, Idorsia’s dual endothelin receptor antagonist, presented at ESC 2019

    author_avatar
    NASDAQ Market News

    Matinas BioPharma Receives Orphan Drug Designation From U.S. FDA for MAT2203 for the Treatment of Cryptococcosis

    author_avatar
    NASDAQ Market News

    Aptose Biosciences to Present at Canaccord Genuity 40th Annual Growth Conference

    author_avatar
    NASDAQ Market News